ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Asahi Kasei moves deeper into pharmaceuticals

by Michael McCoy
November 30, 2019 | APPEARED IN VOLUME 97, ISSUE 47

Asahi Kasei has signed an agreement to acquire Veloxis Pharmaceuticals, a North Carolina–based specialty-drug maker, for about $1.3 billion. Veloxis’s main product is Envarsus XR, a controlled-release immunosuppressant used following kidney transplants. Asahi Kasei says the deal builds on its 2012 purchase of the medical-device maker Zoll Medical. The Japanese firm wants to make health care a third pillar, after its materials and home building businesses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment